Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Cash & Equivalents (2016 - 2023)

Rapid Therapeutic Science Laboratories' Cash & Equivalents history spans 8 years, with the latest figure at $2160.0 for Q2 2023.

  • For Q2 2023, Cash & Equivalents fell 98.07% year-over-year to $2160.0; the TTM value through Jun 2023 reached $2160.0, down 98.07%, while the annual FY2021 figure was $192484.0, 61.44% down from the prior year.
  • Cash & Equivalents for Q2 2023 was $2160.0 at Rapid Therapeutic Science Laboratories, down from $17572.0 in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $919707.0 in Q3 2021 and bottomed at $1334.0 in Q1 2019.
  • The 5-year median for Cash & Equivalents is $124189.5 (2019), against an average of $172987.6.
  • The largest annual shift saw Cash & Equivalents surged 10111.09% in 2020 before it tumbled 98.07% in 2023.
  • A 5-year view of Cash & Equivalents shows it stood at $136215.0 in 2019, then skyrocketed by 266.44% to $499146.0 in 2020, then tumbled by 61.44% to $192484.0 in 2021, then tumbled by 41.73% to $112164.0 in 2022, then crashed by 98.07% to $2160.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Cash & Equivalents are $2160.0 (Q2 2023), $17572.0 (Q1 2023), and $112164.0 (Q2 2022).